Reason for request
Inclusion of the list of medicines reimbursed by National Insurance and approved for use by hospitals. .
Clinical Benefit
| Substantial |
The actual benefit of these drugs is substantial. |
Clinical Added Value
| minor |
INOVELON offers a minor (level IV) improvement in actual benefit in the therapeutic management of patients aged 4 and over with Lennox-Gastaut syndrome that is resistant to first-line treatments. |
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
LarNmGqKADfUevdu
